PriceTargets.com logo

Travere Therapeutics - RTRX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.26 As of 04/26/2024 01:00 AM ET
▼ -0.13 (-2.41%)
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RTRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RTRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.26.

This chart shows the closing price for RTRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Travere Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2020BMO Capital MarketsBoost TargetOutperform$31.00 ➝ $33.00High
9/17/2020WedbushInitiated CoverageOutperform$33.00High
8/24/2020Bank of AmericaInitiated CoverageBuy$30.00Low
7/31/2020BarclaysReiterated RatingHold$21.00Medium
7/13/2020BMO Capital MarketsLower Target$34.00 ➝ $31.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$25.00Low
5/12/2020BMO Capital MarketsBoost TargetOutperform$33.00 ➝ $34.00High
2/25/2020BarclaysDowngradeOverweight ➝ Equal Weight$19.00High
8/23/2019Jefferies Financial GroupSet TargetBuy$33.00N/A
8/23/2019William BlairReiterated RatingBuyHigh
8/23/2019BMO Capital MarketsLower TargetPositive ➝ Outperform$38.00 ➝ $33.00Medium
8/23/2019Nomura SecuritiesLower TargetBuy$57.00 ➝ $33.00Medium
8/23/2019BarclaysLower TargetOverweight$36.00 ➝ $20.00High
8/22/2019BMO Capital MarketsSet TargetBuy$38.00Low
8/22/2019JMP SecuritiesSet TargetBuy$32.00 ➝ $26.00Low
8/8/2019Nomura SecuritiesReiterated RatingBuy$57.00Medium
7/5/2019William BlairReiterated RatingBuyMedium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Travere Therapeutics logo
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $5.26
Low: $5.21
High: $5.56

50 Day Range

MA: $26.56
Low: $24.25
High: $28.18

52 Week Range

Now: $5.26
Low: $8.98
High: $24.96

Volume

1,220,034 shs

Average Volume

412,277 shs

Market Capitalization

$268.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last twelve months:
View the latest analyst ratings for RTRX.

What is the current price target for Travere Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Travere Therapeutics in the next year.
View the latest price targets for RTRX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RTRX.

What other companies compete with Travere Therapeutics?

Other companies that are similar to Travere Therapeutics include Kamada, Neoleukin Therapeutics, Erasca, Verrica Pharmaceuticals and Contineum Therapeutics. Learn More about companies similar to Travere Therapeutics.

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected]. The official website for Travere Therapeutics is www.retrophin.com. Learn More about contacing Travere Therapeutics investor relations.